Endpoint
Gestational diabetes mellitus incidence
CAT:outcome/gestational-diabetes-incidencereported in proportion1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| myo-inositol | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
Reported to move it
1 finding
myo-inositol — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Incidence of GDM was significantly reduced in the myo-inositol group compared with the placebo group: 6 vs. 15.3%, respectively (P = 0.04).”
Quoted verbatim from myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.. - Study
- RCT
- Dose
- 2 g myo-inositol plus 200 µg folic acid twice a day
- Population
- pregnant outpatients with a parent with type 2 diabetes, treated from the end of the first trimester; folic acid 200 µg twice daily given in both arms
myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.2013PMID:23340885Permalink
How it is measured
Proportion of pregnant women with a new diagnosis of gestational diabetes mellitus, made by oral glucose tolerance test (typically 24-28 weeks of gestation) against a stated diagnostic criteria set such as IADPSG, or by medical record diagnosis. The criteria set, the glucose-load protocol and the gestational window of testing are recorded with each finding, since the sets differ in thresholds and in how many abnormal values are required.
Sources cited
1 paper
- Subject
- gestational diabetes mellitus incidence
- Findings
- 1
- Papers
- 1